Bariatric Surgery Beats GLP-1 Drugs for Weight Loss and Saves $11,689 Over 2 Years
Major study of 30,458 patients finds surgery achieves 28% weight loss vs 10% with GLP-1 drugs, while costing significantly less long-term.
Summary
A large-scale study comparing bariatric surgery to GLP-1 receptor agonists (like Ozempic and Wegovy) found surgery delivers nearly triple the weight loss at lower long-term costs. Among 30,458 patients with severe obesity, those who underwent surgery lost 28% of their body weight compared to 10% with GLP-1 drugs. Surgery also saved approximately $11,689 per patient over two years, primarily due to the ongoing high costs of GLP-1 medications. The findings challenge the current approach of using surgery as a "last resort" for obesity treatment.
Detailed Summary
This comprehensive study analyzed real-world outcomes from 30,458 patients with class II and III obesity, comparing metabolic bariatric surgery (MBS) to GLP-1 receptor agonists like semaglutide and tirzepatide. The research used data from a major US insurance database and electronic health records between 2018-2023, with patients followed for an average of 32-34 months.
The weight loss results were striking: patients who underwent bariatric surgery achieved a mean total weight loss of 28.3% compared to just 10.3% for those using GLP-1 drugs (p<0.001). This represents nearly triple the weight loss effectiveness for surgical intervention. The study included 14,101 surgery patients and 16,357 GLP-1 drug users, with propensity score weighting used to adjust for baseline differences.
Economically, the findings were equally compelling. Total costs over two years were $63,483 for GLP-1 users versus $51,794 for surgery patients (p<0.001), representing savings of approximately $11,689 per patient with surgery. The primary cost driver was sustained high pharmacy expenses for GLP-1 medications throughout the second year of follow-up, while surgery had higher upfront costs but minimal ongoing expenses.
The study challenges current treatment paradigms that position bariatric surgery as a "last resort." Given that obesity is a chronic condition requiring long-term management, the superior durability and cost-effectiveness of surgery may warrant earlier consideration. The research included various GLP-1 medications: semaglutide (45% of users), dulaglutide (25%), liraglutide (17%), and tirzepatide (11%), representing real-world prescribing patterns.
These findings have significant implications for healthcare policy and individual treatment decisions, suggesting that the most effective obesity treatment may also be the most economically sustainable long-term option.
Key Findings
- Bariatric surgery achieved 28.3% total weight loss vs 10.3% with GLP-1 drugs (p<0.001)
- Surgery saved $11,689 per patient over 2 years compared to GLP-1 medications
- Total 2-year costs: $51,794 for surgery vs $63,483 for GLP-1 drugs (p<0.001)
- Study included 30,458 patients with mean follow-up of 32-34 months
- Sustained pharmacy costs drove higher expenses in GLP-1 group throughout year 2
- Surgery group included 14,101 patients; GLP-1 group included 16,357 patients
- Semaglutide was most prescribed GLP-1 drug (45% of users), followed by dulaglutide (25%)
Methodology
This retrospective cohort study used Highmark Health insurance claims database and Allegheny Health Network electronic health records from 2018-2023. Patients required 6 months pre-treatment enrollment and minimum 12 months follow-up. Propensity score weighting adjusted for baseline differences in demographics, comorbidities, and healthcare utilization. Statistical analysis used generalized linear mixed models with Poisson distributions for cost outcomes.
Study Limitations
The study was funded by Medtronic (bariatric surgery device manufacturer), creating potential bias. Weight loss data was only available for a subset of patients (257 GLP-1 users vs 1,291 surgery patients). The analysis was limited to 2-year follow-up and may not capture longer-term outcomes. Real-world adherence to GLP-1 medications may differ from clinical trial settings, potentially affecting comparative effectiveness.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.